Key result
Statins and ezetimibe beneficially decrease arterial stiffness in patients with dyslipidaemia, whereas fibrates have no effect and direct data for PCSK9 inhibitors are lacking.
Why the study?
Arterial stiffness is an independent predictor of cardiovascular events, but the extent to which different lipid-lowering drugs affect arterial stiffness and cardiovascular risk remains an important question.
Do lipid-lowering drugs improve arterial stiffness in patients with dyslipidaemia?
Do lipid-lowering drugs improve arterial stiffness in patients with dyslipidaemia?
High-dose statins and ezetimibe improve arterial stiffness in addition to lowering LDL-C, which may contribute to the observed reduction in vascular events.
Answers are grounded in this paper and cite their sources.
May support statin or ezetimibe use for arterial stiffness in dyslipidaemia; leaves open effects of fibrates and PCSK9 inhibitors.
Arterial stiffness (AS) is considered an independent predictor of cardiovascular disease (CVD) events. Among lipid lowering drugs, statins have a beneficial effect on AS, independent of their hypolipidaemic effect. Based on 3 meta-analyses and other studies, this effect is compound- and doserelated. Potent statins at high doses are more effective than less powerful statins. Ezetimibe (± statin) also seems to decrease AS in patients with dyslipidaemia. Fibrates have no effect on AS. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have data that beneficially affect all AS risk factors, suggesting a beneficial effect on artery compliance. However, there is no direct measurement of their effect on AS indices. In patients with dyslipidaemia, prescribing high dose statins (± ezetimibe) will not only decrease low-density lipoprotein cholesterol levels but also improve AS (in addition to other effects). This effect on AS may contribute to the observed reduction in vascular events.
No takes yet. Share an insight, caveat, or question.
Reklou et al. (2019) conducted a review in Dyslipidaemia. Lipid lowering drugs (statins, ezetimibe, fibrates, PCSK9 inhibitors) was evaluated on Arterial stiffness. Statins and ezetimibe beneficially decrease arterial stiffness in patients with dyslipidaemia, whereas fibrates have no effect and direct data for PCSK9 inhibitors are lacking.
Synapse has enriched 10 related papers. Consider them for comparative context: